Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
AG-013736 is a multi-target small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The indication currently approved for marketing is the second-line treatment of advanced renal cell carcinoma, which means that after the failure of Sutan therapy, advanced renal cell carcinoma can be treated with axitinb. In addition to kidney cancer, this drug has also been tried by patients in patients with liver cancer, sarcoma, neuroendocrine tumors and other recognized solid tumors that are more sensitive to anti-angiogenic drugs and have a rich blood supply. It also has a certain effect.
Product Categories : API Intermediates > Intermediate for CAS 319460-85-0
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.